ACCESS Newswire
Aspire Biopharma Announces Successful Pre-IND Meeting with FDA for High-Dose Sublingual Aspirin (OTASA)
📈
AI Sentiment
Highly Positive
8/10
- Home
- ASBP
as of 01-07-2026 11:59am EST
$0.14
+$0.03
+31.84%
Aspire Biopharma Holdings Inc developing next-generation absorption of medicine that will have an impact on the opioid crisis. The group engaged in the business of developing and marketing disruptive technology for novel delivery mechanisms for do-no-harm drugs. Its nanotechnology drug formulation directly targets pain and inflammation bypassing the gastrointestinal tracts.
| Founded: | 2021 | Country: | United States |
| Employees: | N/A | City: | ESTERO |
| Market Cap: | 15.0M | IPO Year: | N/A |
| Target Price: | N/A | AVG Volume (30 days): | 18.1M |
| Analyst Decision: | N/A | Number of Analysts: | N/A |
| Dividend Yield: | N/A | Dividend Payout Frequency: | N/A |
| EPS: | -0.41 | EPS Growth: | N/A |
| 52 Week Low/High: | $0.07 - $15.80 | Next Earning Date: | 02-24-2026 |
| Revenue: | $1,941 | Revenue Growth: | N/A |
| Revenue Growth (this year): | N/A | Revenue Growth (next year): | N/A |
AI-Powered ASBP Daily Prediction
Machine learning model trained on 25+ technical indicators
Updated 17 hours ago
AI Recommendation
hold
Model Accuracy: 65.22%
65.22%
Confidence
Disclaimer: This prediction is generated by an AI model and should not be considered as financial advice. Always conduct your own research and consult with financial professionals before making investment decisions.
Latest Aspire Biopharma Holdings Inc. News
ASBP Breaking Stock News: Dive into ASBP Ticker-Specific Updates for Smart Investing
Compare ASBP vs Leading Stocks
See how ASBP stacks up against similar companies in the market
Head-to-Head Comparisons
Share on Social Networks:
Tools & Resources
Enhance your trading experience with our free tools
Disclaimer
The information presented on this page, "ASBP Aspire Biopharma Holdings Inc. - Stocks Price | History | Analysis", including historical data, forecasts, news, insider information, and predictions, is provided for educational purposes only. It should not be considered as financial advice or a recommendation to buy or sell any securities. Decisions regarding investments should be made only after careful consideration and consultation with a qualified financial advisor. We do not endorse or guarantee the accuracy or reliability of the information provided, and we disclaim any liability for financial losses incurred as a result of decisions made based on the information presented.